Biotech Values

[ciotera]

This would be undeniably true...

Thanks for the clarification, I did not understand that your comment was in the context of response guided therapy. But I think even with RGT optimal pricing is easy to figure out if you know (and are confident of) your expected source of business by patient type.

It's possible that the developers of all oral combinations are starting to move away from RGT in order to avoid this potential pricing dilemma but I think another explanation may be that they expect patients that could benefit from shorter LoT to be gone by 2015 and so they don't want to develop something for a vanishing market.